Glucocorticoids Are Preferable to Thionamides As First-line Treatment for Amiodarone-induced Thyrotoxicosis Due to Destructive Thyroiditis: a Matched Retrospective Cohort Study
Overview
Authors
Affiliations
Context: Type 2 amiodarone-induced thyrotoxicosis (AIT) is a destructive thyroiditis usually responsive to glucocorticoids; however, recent surveys showed that many expert thyroidologists worldwide use thionamides for type 2 AIT patients.
Objective: The objective of the study was to compare the effectiveness of methimazole (MMI) or prednisone (GLU) in type 2 AIT patients who had a short cure time according to a published predictive model.
Design: This was a matched retrospective cohort study.
Setting: The study was conducted at a university center.
Patients: Forty-two untreated type 2 AIT patients with a predicted cure time < or = 40 d were divided into two groups (MMI and GLU groups). After matching for the predicted cure time, patients in the GLU group were selected in a 1:1 ratio to patients in the MMI group.
Intervention: Patients were treated with GLU or MMI for 40 d. Patients still thyrotoxic after 40 d continued glucocorticoids if in the GLU group or were switched to prednisone (MMI-GLU group) if in the MMI group.
Main Outcome Measure: Time and rate of cure (healing) at 40 d were measured.
Results: Patients still thyrotoxic after 40 d were 23.8 +/- 9.3% in the GLU group and 85.7 +/- 7.6% in the MMI group (P = 0.000). The GLU and MMI-GLU groups did not significantly differ in the nonhealing rate at 40 d (P = 0.730). When patients in the MMI group were treated with glucocorticoids, 94.1% patients achieved euthyroidism within 40 d. However, the global median cure time (MMI period + prednisone period) was longer (60 d, 95% confidence interval 53.5-66.5 d) in the MMI-GLU group than the GLU group (21 d, 95% confidence interval 15.1-26.9 d).
Conclusions: Glucocorticoids are the first-line treatment in type 2 AIT, whereas thionamides play no role in this destructive thyroiditis.
Ermolaeva A, Fadeev V Probl Endokrinol (Mosk). 2024; 69(6):17-27.
PMID: 38311991 PMC: 10848191. DOI: 10.14341/probl13267.
Short review: novel concepts in the approach to patients with amiodarone-induced thyrotoxicosis.
Cappellani D, Bartalena L, Bogazzi F J Endocrinol Invest. 2023; 47(2):275-283.
PMID: 37731073 PMC: 10859339. DOI: 10.1007/s40618-023-02168-3.
AMIODARONE AND THYROID DYSFUNCTION.
Medic F, Bakula M, Alfirevic M, Bakula M, Mucic K, Maric N Acta Clin Croat. 2023; 61(2):327-341.
PMID: 36818930 PMC: 9934045. DOI: 10.20471/acc.2022.61.02.20.
Amiodarone-Induced Thyrotoxicosis - Literature Review & Clinical Update.
de Souza L, Campagnolo M, Martins L, Scanavacca M Arq Bras Cardiol. 2021; 117(5):1038-1044.
PMID: 34817015 PMC: 8682089. DOI: 10.36660/abc.20190757.
Bartalena L, Bogazzi F, Chiovato L, Hubalewska-Dydejczyk A, Links T, Vanderpump M Eur Thyroid J. 2018; 7(2):55-66.
PMID: 29594056 PMC: 5869486. DOI: 10.1159/000486957.